Clinical trial
AMD3100 (Plerixafor) Added to a Mobilizing Regimen of Granulocyte-colony…
NCT00396201 · Genzyme, a Sanofi Company, Industry · Completed
Key facts
| NCT number | NCT00396201 |
|---|---|
| Title | AMD3100 (Plerixafor) Added to a Mobilizing Regimen of Granulocyte-colony Stimulating Factor (G-CSF) to Increase the Number of Peripheral Blood Stem Cells (PBSCs) in Patients With Hodgkin's Disease |
| Official title | Treatment With AMD3100 Added to a Mobilizing Regimen of G-CSF to Increase the Number of Peripheral Blood Stem Cells in Patients With Hodgkin's Disease |
| Lead sponsor | Genzyme, a Sanofi Company, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Hodgkin's Disease |
| Intervention type | Drug |
| Interventions | G-CSF Plus Plerixafor |
| Enrollment | 22 |
| Start date | Nov 1, 2004 |
| Primary completion | Oct 1, 2006 |
| Completion | Jan 1, 2008 |
| First posted | Nov 6, 2006 |
| Last update posted | Mar 13, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: